Showing Results for
- Academic Journals (95)
Search Results
- 95
Academic Journals
- 95
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer...
-
From:eLife (Vol. 10) Peer-ReviewedPoly(ADP-ribose) polymerase 1 (PARP1) is an important player in the response to DNA damage. Recently, Histone PARylation Factor (HPF1) was shown to be a critical modulator of the activity of PARP1 by facilitating...
-
From:eLife (Vol. 7) Peer-ReviewedIn 2016, as part of the Reproducibility Project: Cancer Biology (https://osf.io/e81xl/wiki/home/), we published a Registered Report (Vanden Heuvel et al., 2016), that described how we intended to replicate selected...
-
From:Oncology (Vol. 35, Issue 4) Peer-ReviewedOvarian cancer is the fifth most common cause of cancer deaths in women and the leading cause of death among cancers of the female reproductive system in the United States. More than 21,400 women in the United States are...
-
From:Nature Medicine (Vol. 22, Issue 2) Peer-ReviewedPoly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials (1). One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently...
-
From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-ReviewedMetastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose...
-
From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-ReviewedDespite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic...
-
From:Oncology (Vol. 34, Issue 10) Peer-ReviewedBACKGROUND: Early-phase clinical trials are critical to the advancement of cancer care, especially in patients with pancreatic ductal adenocarcinoma, given its aggressive nature and limited available therapeutic options....
-
From:Biochemistry and Cell Biology (Vol. 98, Issue 1) Peer-ReviewedFK506-binding proteins (FKBPs) alter the conformation of proteins via cis--trans isomerization of prolyl-peptide bonds. While this activity can be demonstrated in vitro, the intractability of detecting prolyl...
-
From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-ReviewedBackground PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are...
-
From:PLoS ONE (Vol. 13, Issue 12) Peer-ReviewedThe incidence of Human Papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing rapidly in the UK. Patients with HPV-positive OPSCC generally show superior clinical responses relative...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 37, Issue 1) Peer-ReviewedBackground Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy. Combination strategies,...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-ReviewedBackground PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and...
-
From:Oncology (Vol. 35, Issue 3) Peer-ReviewedThe recent advances in immunotherapy have revolutionized cancer care and ushered in an era of true precision medicine. But to best utilize these extraordinary therapies, oncologists must be able to recognize specific...
-
From:Oncology (Vol. 33, Issue 11) Peer-ReviewedThe ESMO Congress was held in Barcelona from September 27 to October 1, 2019. The conference recognized excellence in translational research and focused on clinically important indings and multidisciplinary topics....
-
From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-ReviewedTP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The...
-
From:Oncology (Vol. 35, Issue 10) Peer-ReviewedThe authors of this timely review are to be applauded for providing a comprehensive analysis of the current literature supporting guidelines-based indications for germline testing in prostate cancer. As they describe,...
-
From:Oncology (Vol. 33, Issue 7) Peer-ReviewedThe US Food and Drug Administration (FDA) recently approved a new indication for olaparib (Lynparza) for maintenance treatment in adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer....
-
From:American Family Physician (Vol. 103, Issue 3) Peer-ReviewedTargeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal antibodies, small molecule...
-
From:Oncology (Vol. 35, Issue 7) Peer-ReviewedUntil 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens (methotrexate/vinblastine/doxorubicin/cisplatin;...